A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Financial Summary
| Share Statistics | CSCID | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $5.4 | $252.6 | 4% |
|
| Shares Out (Mil) | 1.0 | 52.3 | 5% |
|
| Institutional Ownership | 0.0% | 92.1% | 0% |
|
| Float (Mil) | na | 40.2 | na |
|
| Beta | 1.90 | 0.95 | 91% |
|
| Avg Daily Volume (000s) | 2 | 455 | 9% |
|
| Price Change (52-week) |
(49.8%) | 52.9% | 16% |
|
| Growth | CSCID | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 15.2% | 13.6% | 73% |
|
| Net Income (5yr) | (15.3%) | (9.9%) | 25% |
|
| EPS (5yr) | 23.5% | 16.0% | 73 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.7%) | (15.6%) | 47% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | CSCID | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $8 | $38 | 8% |
|
| Net Income (TTM) (Mil) | $4 | ($43) | 43% |
|
| EPS (TTM) | $3.843 | ($1.600) | 83% |
|
| Operating Cash Flow (TTM) (Mil) | ($9) | ($31) | 20% |
|
| Net Cash Flow (TTM) (Mil) | ($9) | $5 | 31% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $5 | 20% |
|
| Enterprise Value (Q1) (Mil) | $3 | $180 | 5% |
|
| Valuation | CSCID | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.56 | na |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | CSCID | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 37.4% | 63.8% | 46% |
|
| Net Margin | 50.7% | (67.3%) | 97% |
|
| ROA | 16.2% | (49.8%) | 94% |
|
| ROE | 31.8% | (55.5%) | 88% |
|
| Liabilities to Assets | 18.7% | 30.3% | 12% |
|
| F-Score | na | 3 | na |
|
COSCIENS Biopharma Inc. did not pass any screens on 7/31/2026.
